Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Should Routine Screening for Prostate-Specific Antigen Be Recommended?

Should Routine Screening for Prostate-Specific Antigen Be Recommended? CONTROVERSIES IN INTERNAL MEDICINE SECTION EDITOR: FARRELL J. LLOYD, MD, MPH; SECTION COEDITOR: ADRIANE BUDAVARI, MD Should Routine Screening for Prostate-Specific Antigen Be Recommended? Siam Oottamasathien, MD; E. David Crawford, MD OUTINE SCREENING for only cause for this decline remains differentiated) will not be detected 11,12 prostate cancer re- unknown. Currently, large-scale, ran- with PSA testing. This is another mains a controversial domized prospective trials compar- argument in support for the use of topic. Prostate can- ing screening to “usual clinical care” PSA screening. R cer is the most com- are under way (including the Euro- Before PSA testing, digital rec- mon cause of cancer of men in the pean Randomized Study of Screen- tal examination (DRE) was the only United States and caused more than ing for Prostate Cancer and the Pros- method available to detect prostate 30000 deaths in 1999. It involves a tate, Lung, Colorectal, and Ovarian cancer. It is evident that PSA testing wide pathophysiologic spectrum, Cancer Screening [PLCO] Trial in detects more tumors and tumors in from indolent disease to rapid growth the United States) and will no doubt earlier stages than DRE alone. A re- and metastasis. A continued in- shed some light http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Should Routine Screening for Prostate-Specific Antigen Be Recommended?

Loading next page...
 
/lp/american-medical-association/should-routine-screening-for-prostate-specific-antigen-be-recommended-Zw5qzl1DVM
Publisher
American Medical Association
Copyright
Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinte.163.6.661
Publisher site
See Article on Publisher Site

Abstract

CONTROVERSIES IN INTERNAL MEDICINE SECTION EDITOR: FARRELL J. LLOYD, MD, MPH; SECTION COEDITOR: ADRIANE BUDAVARI, MD Should Routine Screening for Prostate-Specific Antigen Be Recommended? Siam Oottamasathien, MD; E. David Crawford, MD OUTINE SCREENING for only cause for this decline remains differentiated) will not be detected 11,12 prostate cancer re- unknown. Currently, large-scale, ran- with PSA testing. This is another mains a controversial domized prospective trials compar- argument in support for the use of topic. Prostate can- ing screening to “usual clinical care” PSA screening. R cer is the most com- are under way (including the Euro- Before PSA testing, digital rec- mon cause of cancer of men in the pean Randomized Study of Screen- tal examination (DRE) was the only United States and caused more than ing for Prostate Cancer and the Pros- method available to detect prostate 30000 deaths in 1999. It involves a tate, Lung, Colorectal, and Ovarian cancer. It is evident that PSA testing wide pathophysiologic spectrum, Cancer Screening [PLCO] Trial in detects more tumors and tumors in from indolent disease to rapid growth the United States) and will no doubt earlier stages than DRE alone. A re- and metastasis. A continued in- shed some light

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Mar 24, 2003

References